Edition:
United Kingdom

Madrigal Pharmaceuticals Inc (MDGL.OQ)

MDGL.OQ on NASDAQ Stock Exchange Capital Market

111.62USD
7:50pm GMT
Change (% chg)

$-1.42 (-1.26%)
Prev Close
$113.04
Open
$113.09
Day's High
$114.23
Day's Low
$107.86
Volume
75,803
Avg. Vol
92,989
52-wk High
$325.58
52-wk Low
$77.00

Chart for

About

Madrigal Pharmaceuticals, Inc., formerly Synta Pharmaceuticals Corp., is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and nonalcoholic steatohepatitis (NASH). The Company's lead product,... (more)

Overall

Beta: 0.82
Market Cap(Mil.): $586.42
Shares Outstanding(Mil.): 12.50
Dividend: --
Yield (%): --

Financials

  MDGL.OQ Industry Sector
P/E (TTM): -- 92.25 33.63
EPS (TTM): -3.37 -- --
ROI: -70.04 0.28 15.02
ROE: -70.04 0.94 16.60

Viking shares surge after fatty liver drug trial

Viking Therapeutics Inc's shares more than doubled in value on Tuesday after promising data from a mid-stage trial of its fatty liver drug were seen as topping that from larger rival Madrigal Pharmaceuticals .

18 Sep 2018

U.S. hedge funds bet on retail, tech in second-quarter as economy sizzled

Prominent hedge fund managers appeared to make big second-quarter bets that the U.S. economy would continue to expand despite increasing concerns about a broadening trade dispute between the United States and China, regulatory filings showed Tuesday. | Video

14 Aug 2018

WRAPUP 2-U.S. hedge funds bet on retail, tech in Q2 as economy sizzled

Aug 14 Prominent hedge fund managers appeared to make big second-quarter bets that the U.S. economy would continue to expand despite increasing concerns about a broadening trade dispute between the United States and China, regulatory filings showed Tuesday.

14 Aug 2018

Deals of the day-Mergers and acquisitions

June 13 The following bids, mergers, acquisitions and disposals were reported by 2020 GMT on Wednesday:

13 Jun 2018

Madrigal Pharma explores sale: Bloomberg

Madrigal Pharmaceuticals Inc is exploring a sale, Bloomberg reported on Wednesday, citing people familiar with the matter, nearly three weeks after the company reported mid-stage data from its drug to treat non-alcoholic steatohepatitis or NASH.

13 Jun 2018

Madrigal Pharma explores sale - Bloomberg

June 13 Madrigal Pharmaceuticals Inc is exploring a sale, Bloomberg reported https://www.bloomberg.com/news/articles/2018-06-13/madrigal-pharma-is-said-to-explore-sale-amid-takeover-interest on Wednesday, citing people familiar with the matter, nearly three weeks after the company reported mid-stage data from its drug to treat non-alcoholic steatohepatitis or NASH.

13 Jun 2018

Earnings vs. Estimates